In This Article:
In the last week, the United States market has been flat, but over the past 12 months, it has risen by 8.4%, with earnings expected to grow by 14% per annum in the coming years. In this environment, identifying high-growth tech stocks can be crucial for investors seeking to capitalize on potential opportunities within a dynamic sector poised for expansion.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.44% | 29.79% | ★★★★★★ |
| TG Therapeutics | 26.03% | 37.60% | ★★★★★★ |
| Alkami Technology | 20.46% | 85.16% | ★★★★★★ |
| Travere Therapeutics | 28.40% | 64.74% | ★★★★★★ |
| Clene | 60.86% | 63.07% | ★★★★★★ |
| AVITA Medical | 27.91% | 55.77% | ★★★★★★ |
| TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.69% | 58.49% | ★★★★★★ |
| Lumentum Holdings | 21.61% | 120.49% | ★★★★★★ |
| Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
AvePoint
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AvePoint, Inc. offers a cloud-native data management software platform across various regions including North America, Europe, the Middle East, Africa, and the Asia Pacific with a market cap of $3.05 billion.
Operations: The company generates revenue primarily from its software and programming segment, amounting to $330.48 million.
AvePoint is actively pursuing growth through strategic acquisitions and investments, particularly focusing on enhancing its SaaS offerings and expanding global reach. This approach is underscored by their recent announcement of new data security solutions for Google Workspace, aiming to bolster their position in multi-cloud environments—a critical move as 89% of enterprises use multiple cloud services. Financially, AvePoint forecasts robust revenue growth with expectations set at $380 million to $388 million for 2025, marking an increase of up to 17% year-over-year. This projection aligns with their aggressive expansion strategy in the tech sector, where cloud adoption and data security are becoming increasingly paramount.
-
Navigate through the intricacies of AvePoint with our comprehensive health report here.
-
Explore historical data to track AvePoint's performance over time in our Past section.
Incyte
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics across the United States, Europe, Canada, and Japan with a market cap of $11.79 billion.
Operations: Incyte generates revenue primarily from its biotechnology segment, which amounts to $4.24 billion. The company's focus is on developing and commercializing therapeutics across major global markets including the United States, Europe, Canada, and Japan.